Issue 5/2015

Biomarkers for determination prostate cancer: implication for diagnosis and prognosis (683 — 691)

S. ZIARAN, Z. VARCHULOVA NOVAKOVA, D. BOHMER, L. DANISOVIC

DOI: 10.4149/neo_2015_082

Diagnostics and treatment of insulinoma (692 — 704)

M. KOREN, S. KINOVA

DOI: 10.4149/neo_2015_083

MicroRNA-141 regulates the tumour suppressor DLC1 in colorectal cancer (705 — 712)

P. P. WU, H. Y. ZHU, X. F. SUN, L. X. CHEN, Q. ZHOU, J. CHEN

DOI: 10.4149/neo_2015_084

Anti-tumor immunity elicited by cross-linking vaccine heat shock protein 72 and alpha-fetoprotein epitope peptide (713 — 721)

Z. LI, X.P. WANG,, H.P. LIN, B. XU, Q. ZHAO, B.N. QI, Y.X. YANG, Z.R. WANG

DOI: 10.4149/neo_2015_085

Influence of different chemical agents (H2O2, t-BHP and MMS) on the activity of antioxidant enzymes in human HepG2 and hamster V79 cells; relationship to cytotoxicity and genotoxicity (722 — 732)

D. SLAMENOVA, K. KOZICS, M. MELUSOVA,, E. HORVATHOVA

DOI: 10.4149/neo_2015_086

Identification of potential therapeutic targets for melanoma using gene expression analysis (733 — 739)

L. QUAN, J. SHI, Y. TIAN, Q. ZHANG, Y. ZHANG, Y. ZHANG, Q. HUI, K. TAO

DOI: 10.4149/neo_2015_087

Rapamycin-topotecan combination exhibited enhanced antitumor efficacy compared to topotecan used alone in cisplatin-resistant ovarian cancer cells (740 — 747)

G. SUN, Z. GUO, X. LI

DOI: 10.4149/neo_2015_088

Downregulation of PLK1 by RNAi attenuates the tumorigenicity of esophageal squamous cell carcinoma cells via promoting apoptosis and inhibiting angiogenesis (748 — 755)

C. L. ZHAO, J. Y. JU, W. GAO, W. J. YU, Z. Q. GAO, W. T. LI

DOI: 10.4149/neo_2015_089

Identification of genes in ulcerative colitis associated colorectal cancer based on centrality analysis of co-expression network (756 — 764)

J. ZHU, C. LI, W. JI

DOI: 10.4149/neo_2015_090

Association of BCSC-1 with human esophageal squamous cell carcinoma (765 — 769)

C. L. ZHAO, W. J. YU, Z. Q. GAO, W. T. LI, W. GAO, W. W. YANG, W. G. FENG, J. Y. JU

DOI: 10.4149/neo_2015_091

53BP1 foci as a marker of tumor cell radiosensitivity (770 — 776)

E. MARKOVA,, S. VASILYEV, I. BELYAEV

DOI: 10.4149/neo_2015_092

Results and prognostic factors of 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for esophageal carcinoma (777 — 786)

L. TAN, Z. XIAO, H. ZHANG, D. CHEN, Q. FENG, Z. ZHOU, J. LV, J. LIANG, Z. HUI, L. WANG, W. YIN

DOI: 10.4149/neo_2015_093

Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16μg/kg/day: efficacy and safety (787 — 792)

M. KREJCI, A. JANIKOVA, F. FOLBER, Z. KRAL, J. MAYER

DOI: 10.4149/neo_2015_094

Salvage chemotherapy in metastatic colorectal cancer with the combination of capecitabine and mitomycin C (793 — 797)

A. L. ZYGULSKA, K. KRZEMIENIECKI

DOI: 10.4149/neo_2015_095

Factors influencing circulating MicroRNA level in the studies of hepatocellular carcinoma biomarker (798 — 804)

Y. WANG, Z. LIANG, Y. GAO, D. ZHAI, Q. RAO, W. SHI, B. YANG, L. JING, H. GUO, T. LIU, J. LIU, Z. DU

DOI: 10.4149/neo_2015_096

Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to patients with acute lymphoblastic leukemia (805 — 811)

L. RAIDA, Z. RUSINAKOVA, R. SZOTKOWSKA, A. KUBA, E. FABER, P. ROHON, T. SZOTKOWSKI, J. HUBACEK, Z. PIKALOVA, M. JAROSOVA, M. DIVOKA, K. INDRAK, K. LANGOVA, I. SKOUMALOVA, T. PAPAJIK

DOI: 10.4149/neo_2015_097

Improved outcome for children and adolescent with acute lymphoblastic leukemia in the first decade of the 21st century: A report from the Slovak Republic (812 — 820)

A. KOLENOVA, E. KAISEROVA, M. MAKOHUSOVA,, Z. SUBOVA, E. BUBANSKA, I. ORAVKINOVA, P. SVEC, O. FABRI, S. P. HUNGER, S. SUFLIARSKA, S. HORAKOVA, V. MRAZOVA, J. STARY

DOI: 10.4149/neo_2015_098

A 39-gene signature is associated with early occurrence of distant metastasis in primary lymph-node negative breast cancers (821 — 826)

R. XIA, S. CHEN, W. ZHANG, Y. CHEN, R. ZHU, A. DENG

DOI: 10.4149/neo_2015_099

Immunoparesis in MGUS – Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories (827 — 832)

T. PIKA, P. LOCHMAN, V. SANDECKA, V. MAISNAR, J. MINARIK, M. TICHY, J. ZAPLETALOVA, L. SOLCOVA, V. SCUDLA, R. HAJEK

DOI: 10.4149/neo_2015_100

Pol ζ polymorphisms are associated with platinum based chemotherapy response and side effects among non-small cell lung cancer patients (833 — 839)

J. YE, T. CHU, R. LI, Y. NIU, B. JIN, J. XIA, M. SHAO, B. HAN

DOI: 10.4149/neo_2015_101